[HTML][HTML] Recent advances of PET imaging in clinical radiation oncology

M Unterrainer, C Eze, H Ilhan, S Marschner… - Radiation …, 2020 - Springer
Radiotherapy and radiation oncology play a key role in the clinical management of patients
suffering from oncological diseases. In clinical routine, anatomic imaging such as contrast-…

[HTML][HTML] PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions

C Eze, NS Schmidt-Hegemann, LM Sawicki… - European journal of …, 2021 - Springer
Purpose The advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment
of advanced NSCLC, leading to a string of approvals in recent years. Herein, a narrative …

[HTML][HTML] Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel …

L Käsmann, C Eze, J Taugner, O Roengvoraphoj… - Radiation …, 2020 - Springer
Immune-checkpoint inhibitors (ICI) have dramatically changed the landscape of lung cancer
treatment. Preclinical studies investigating combination of ICI with radiation show a …

Outcome after PSMA PET/CT–based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a 2-institution retrospective analysis

…, C Stief, TH Kim, C Eze… - Journal of Nuclear …, 2019 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) PET/CT detects prostate cancer recurrence at
low levels of prostate-specific antigen (PSA). Radiotherapy with dose escalation to the former …

[HTML][HTML] Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate

L Nierer, C Eze, V da Silva Mendes, J Braun, P Thum… - Radiation …, 2022 - Springer
Background Hybrid magnetic resonance (MR)-Linac systems have recently been introduced
into clinical practice. The systems allow online adaption of the treatment plan with the aim of …

[HTML][HTML] Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy

…, H Ilhan, A Herlemann, A Buchner, C Stief, C Eze… - Radiation …, 2018 - Springer
Background PSMA PET/CT visualises prostate cancer residual disease or recurrence at
lower PSA levels compared to conventional imaging and results in a change of treatment in a …

Impact of 68Ga-PSMA PET/CT on the radiotherapeutic approach to prostate cancer in comparison to CT: a retrospective analysis

NS Schmidt-Hegemann, C Eze, M Li… - Journal of Nuclear …, 2019 - Soc Nuclear Med
68 Ga-prostate-specific membrane antigen PET/CT ( 68 Ga-PSMA PET/CT) offers
unprecedented accuracy for staging of primary, persistent, or recurrent prostate cancer. Thus, we …

[HTML][HTML] Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients

J Taugner, L Käsmann, C Eze, A Rühle… - Investigational new …, 2021 - Springer
The aim of this prospective study is to evaluate the clinical use and real-world efficacy of
durvalumab maintenance treatment after chemoradiotherapy (CRT) in unresectable stage, …

[HTML][HTML] Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with …

K Gennen, L Käsmann, J Taugner, C Eze, M Karin… - Radiation …, 2020 - Springer
Background/aim mmune checkpoint inhibition (CPI) has an increasing impact in the
multimodal treatment of locally advanced non-small cell lung cancer (LA-NSCLC). Increasing …

[HTML][HTML] Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy

…, A Buchner, C Stief, P Rogowski, M Niyazi, C Eze… - Radiation …, 2017 - Springer
Background To determine the potential role of 68 Ga-PSMA positron emission tomography/computed
tomography (PET/CT) in radiotherapy (RT) planning for prostate cancer (PCa). …